Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 552 participants.

Also called NCT01630369

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 552 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01630369
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01630369. Non-randomized; no masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2013-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes
Acronym
SPIRIT
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
insulin human (HR1799)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01630369
Content hash
8ee693be7922c895961f0d15253341cdf2092eba7f1b80471d64bbf2ca53059c